4-(TRIFLUOROMETHYL)BENZYL BROMIDE

We are 4-(TRIFLUOROMETHYL)BENZYL BROMIDE CAS:402-49-3 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:4-(TRIFLUOROMETHYL)BENZYL BROMIDE
CAS.NO:402-49-3
Synonyms:α-Bromo-α',α',α'-trifluoro-p-xylene; 
1-(bromomethyl)-4-(trifluoromethyl)benzene; 
4-(TrifluoroMethyl)benzyl BroMide; 
4-(Bromomethyl)benzotrifluoride; 
alpha‘-Bromo-alpha,alpha,alpha-trifluoro-p-xylene;
Molecular Formula:C8H6BrF3
Molecular Weight:239.03200
 
Physical and Chemical Properties:
Density:1.546;
Melting point:29-33oC;
Boiling point:65-69oC;
Flash point:192oF;
Index of Refraction:1.484;
 
Specification:
Appearance:White to light yellow low melting solid
Purity(GC):≥99.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate for organic synthesis

4-(TRIFLUOROMETHYL)BENZYL BROMIDE


Related News: “CAR T-cell therapy continues to deliver remarkable outcomes for patients with hematologic malignancies, and next-generation approaches are needed to enable broad and timely patient access and reduce the cost and complexity of therapy,” said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics.2-hidroxi-4-metoxibenzaldehído CAS:673-22-3 Featured APIs: Production capacity continues to expand, targeted patents expire. Original research drugs: industry entry barriers are high, performance stability and certainty are high.4-Amino-2,6-dichlorophenol CAS:5930-28-9 Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with an initial focus on Myelodysplastic Syndromes (MDS).2-methylpyridin-3-amine An effective treatment for Alzheimer’s, which is estimated in 60%-70% of around 50 million dementia cases worldwide, could become one of the best-selling drugs globally.Patents covering oral and injectable rigosertib have been issued in the US and are expected to provide coverage until at least 2037.

Related Products
Product Name
1-Bromo-7-chloroheptane View Details
N-butyl-N-[(dibutylamino)disulfanyl]butan-1-amine View Details
glycerone View Details
(1S,3S,5S)-tert-Butyl 3-carbamoyl-2-azabicyclo[3.1.0]hexane-2-carboxylate manufacturer 6-bromohex-1-ene manufacturer 1,1,3,3-Tetramethyl-1,3-Divinyldisilazane manufacturer 2-Methyl-4-nitrobenzoic acid manufacturer 3-Bromo-N,N,N-trimethylpropan-1-aminium bromide Cas:3779-42-8 manufacturer